CD19 and B-cell non-Hodgkin lymphoma: Multiple randomized trials are currently enrolling patients with primary refractory or early relapsed aggressive B-cell lymphomas comparing anti-CD19 CAR T cell therapy with traditional salvage therapy and ASCT (TRANSFORM, NCT03575351; BELINDA, NCT03570892; and ZUMA-7, NCT03391466) [39].